NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
National Clinical Guideline Centre (UK). Osteoarthritis: Care and Management in Adults. London: National Institute for Health and Care Excellence (UK); 2014 Feb. (NICE Clinical Guidelines, No. 177.)
Update information: December 2020: in the recommendation on adding opioid analgesics NICE added links to other NICE guidelines and resources that support discussion with patients about opioid prescribing and safe withdrawal management. For the current recommendations, see www.nice.org.uk/guidance/CG177/chapter/recommendations.
| GDG meeting | Declaration of Interests | Action taken |
|---|---|---|
| First GDG meeting 27 February 2012 | Chair (PC) Declared personal non pecuniary interests: PC is since 2008 the Chair for the Arthritis Research UK Osteoarthritis Clinical Studies Group. Responsible for national OA clinical research consensus priority setting and promotion of investigator initiated studies. The funding goes to his department. PC is since 2010 a scientific committee member SORT study (Survey of Osteoarthritis Real World Therapies), which is an academic collaboration funded by Merck to his department. He is also the principal investigator on analysis of GPRD database of how GPs prescribe for OA and trends before and after last NICE guidance. Again, this is an academic collaboration. Not product specific and no funding involved. Astra Zeneca product in this field was not licensed for the period of the analysis. PC is on the steering committee member (not PI) on randomised trial of combination pill versus celecoxib 200mg. Trial requested by Spanish regulatory authorities. Bioiberica. This combination pill is not licensed in UK and he doesn’t know if application is being made. This would therefore not be under NICE consideration and would be willing to withdraw if such application is made. In May 2011 he was a Speaker at the Spanish Society of Rheumatology, talk entitled “Osteoarthritis Imaging: Diagnostic and Predictive Value”, and received a one-time personal payment from Bioiberica. PC was also a speaker at RCP London, talk entitled “OA Overview – state of the art lecture” which was sponsored by mundipharm. Since March 2012 he has also acted as an advisor for Arthritis Care OA Nation 2012 report – a survey of OA impact in the community, which is unrelated to the guideline scope. Declared a personal pecuniary interest: In March 2012 he had a collaboration on development of bone-related therapy for OA and received a personal payment for advisory meetings from Servier. Strontium is not part of the guideline update scope. MD Declared personal pecuniary interest: Dec 2011: Advisory Board Servier (strontium in OA) – non-specific Sept 2011: Advisory Board Novartis (low dose, over-the-counter diclofenac versus paracetamol and placebo for OA) – non-specific Co-author of BMJ Evidence Series on OA (unpaid) Member of EULAR Guideline Development group for non-pharmacological management of knee and hip OA, 2011–2012 (unpaid) OARSI primer on OA (unpaid) Co-Editor of OUP Osteoarthritis (3rd Ed – in preparation) (shared royalties from sales) Member of Arthritis Research UK OA Clinical Study Group 2007-now (unpaid) KD Declared a personal non pecuniary interest: Has two conference presentations at the forthcoming EULAR 6–9 June 2012 conference. As an invited speaker she has travel, accommodation and the conference fee paid and accommodation for an accompanying person. It relates to research for a study where she already holds a grant for a funded project implementing the NICE OA guidelines in primary care - the MOSAICS study Managing osteoarthritis in consultations. WZ Declared personal non-pecuniary interests: Member of the Arthritis Research UK Implementation Fellowship Committee (2011 to 2015) - unpaid Member of the Osteoarthritis & Cartilage Editorial Board - unpaid Member of the Advisory Board for Cochrane Musculoskeletal Disease Group - unpaid Lead investigator of the OARSI Treatment Guidelines - 2006 to 2011 with a grant of $10,000 annually for monitoring and updating research evidence in OA Co-author for the BMJ Clinical Evidence for OA – unpaid Declared personal pecuniary interests: Invited lecture on “How can we treat OA? - from research to clinical practice” for the 2rd International Symposium on Musculoskeletal System and Pain, 27–28 July 2012 Sapporo, Japan with travel, hotel and honorarium from the Japanese Orthopaedic Society. The honorarium for the Japanese lecture is £783. Invited lecture on “Is placebo a possible therapy for OA?” for the 13th Psychiatric Summer School - Placebo effects in musculoskeletal disorders, 16–17 August 2012 Helsinki Finland, travel and hotel paid by the Rehabilitation ORTON Foundation. Invited lecture on “The impact of context in pain outcomes” for the Annual Congress of the British Society of Pain, 25–28 April 2012 Liverpool, travel and hotel paid by the Society. BL Declared personal non pecuniary interests: Chair of Royal College of Nursing’s Society of Orthopaedic and Trauma Nursing (unpaid and in own time) Also on the editorial board of the International Journal of Orthopaedic and Trauma Nursing. EW Declared a non personal pecuniary interest: Received an educational grant for £1000 towards travel/accommodation to the American College of Rheumatology Meeting from Pfizer Speaker fees/travel/accommodation from Pfizer UK for a European Primary Care Meeting Locum fees/travel/accommodation from Napp. Declared personal pecuniary interests : Chair the BMJ musculoskeletal masterclass which includes a sponsored presentation. Does not receive any money from the sponsors and receives travel/accommodation/locum fees and speaker fees from BMJ publishing only. Has arranged a local meeting for the Royal College of General Practitioners which was sponsored. Did not receive any money or expenses for the meeting. Is a member of a local GPSI group which receives support from Pfizer (i.e. they arrange a room for the meeting). She will be involved in two meetings arranged by Servier. The first is an ad board - her surgery received recompense for her time. She did not receive travel expenses for this meeting as it was on her way home. The second meeting was an internal Servier meeting for their medical representatives. She did an hour’s presentation on osteoarthritis from a primary care perspective. They funded her flight and taxi to the meeting but did not fund her return home. They have provided an honorarium which is going to her surgery to cover locum expenses. Is a member of the Primary Care Rheumatology Society which receives funding from different drug companies. FB Declared non personal pecuniary interests: commercial trial recruitment in osteoarthritis 2008–2011 servier. Speaker honoraria 2011 Amgen, Menarini Chairing steering committee and meetings for IQ Leaders – generic leadership skills programme for high achieving new consultants 2011-Litms Pfizer Chaired national advisory board on glucosamine sulphate oral power 5/5/11 HFA health care Expert consultant for MHRA appeal on civamide 8/4/11 Winston Pharmaceuticals All honoraria have been put into research accounts IB Declared a pecuniary interest: He received a consultancy fee in June 2011 for acting as a clinical advisor to InHealth Ltd with respect to their tender application to run NHS musculoskeletal services in South Tyneside NHS Trust. He received a fee in September 2011 for acting as a course organiser funded by InHealth Ltd, to run a GP education programme about musculoskeletal services. He is paid an NHS salary for service development work including acting as an MSk clinical advisor to: Ealing Clinical Commissioning Group, NHS Ealing, Outer NW London PCTs Sub-Cluster, NHS NW London, NHS London, Department of Health. JC Declared non-personal pecuniary interests: Arthritis Care as received educational grants from Roche with regards to publications for children with JIA and also a school bag competition. None of these involved me or my former department the Helplines service. Arthritis Care received a one off honorarium for a speaking engagement organised by Astra Zeneca. This did not come to me or my department. 2011 –2012 - Arthritis Care has received educational grants from Pfizer, NAPP, Sanofi and Astra Zeneca to conduct a survey of people living with OA across the UK. This has been an independent project within Arthritis Care and has not attracted any funding to myself individually or to my former or current departments. Arthritis Care has recently received an educational grant relating to work with Servier which has included a one off presentation me. This has not come either to me or my current department. MP Declared a personal non-pecuniary interest: He works as a Lecturer in General Practice at the Arthritis Research UK Primary Care Centre at Keele University. In this role he writes, presents and publishes academic papers on osteoarthritis, is invited to speak at academic and educational meetings on osteoarthritis (most recently for the EULAR Conference - June 2012 - on the role of GPs in supporting the self-management of osteoarthritis) and writes and publishes educational articles (most recently for Arthritis Research UK - edition of Hands on osteoarthritis and an article for their Arthritis Today magazine on osteoarthritis). He is currently a member of the panel advising Arthritis Care on undertaking and disseminating the findings of their OA Nation survey. Declared a non personal pecuniary interest: The Centre receives funding from various funding bodies but not from any pharmaceutical companies. He does not receive speaker fees for presenting at conferences or other meetings but am reimbursed travel and accommodation expenses. His role with Arthritis Care is unpaid. TW Declared a personal non pecuniary interest: He is a member of the Governing Body of Sheffield LINk, of his local GP Practice Patient Group, of a Cardiac network user group and of the north Sheffield Patient group. He is an occasional representative service user / carer / lay member to the Sheffield University Psychology Unit on terms of lecturing / advisor / supporting Family related interest: His elder son is a Consultant Anaesthetist in Sheffield PK Declared non-personal pecuniary interests : Part of a large specialist Orthopaedic and Rheumatology Hospital (Wrightington) providing patient services for osteoarthritis. The Institution has and continues to receive research funding from orthopaedic implant and pharmacological companies for patients suffering from Osteoarthritis. Declared: Personal non-pecuniary interest: President of the British Orthopaedic Association (Until Sept 2011) who’s aims are
RM Declared a personal pecuniary interest: Consultancy services and implant design to Orthopaedic Implant Industry [Zimmer, DePuy, Lima, WG Healthcare, Finsbury]. Declared personal non-pecuniary interests: Principle Investigator or Participating Investigator in research trials into the outcomes of hip replacements sponsored by Implant manufactures (Zimmer, Smith & Nephew, Lima). Lectures, Podcasts, Publications, and Workshops Nationally and Internationally on Enhanced Recovery, Rapid Improvement Programmes in Orthopaedics, Hip Replacement, Osteoarthritis and Exercise. Orthopaedic Surgeon with NHS and Private Practice in the surgical treatment of Osteoarthritis. Director of Health decoded a healthcare management consultancy working in hospitals to improve quality and efficiency of care. VDN Declared a family interest. Her partner is director of a health economics consultancy company which receives payment from the pharmaceutical industry and other consultancy companies. | |
| 16 April 2012 | IB Declared a personal non-pecuniary interest: Is a clinical advisor to ARMA (Arthritis and Musculoskeletal Alliance - an umbrella organisation representing professional bodies and patient groups in the musculoskeletal community in the UK) and to BIMM (British Institute of Musculoskeletal Medicine - a professional special interest organisation). Both of these roles are voluntary and he receives no fee or anything else in kind. PK Declared a personal pecuniary interest: Taught on a Johnson and Johnson Hip Replacement Course as part of a National Arthroplasty Meeting (Japan) and will receive reimbursement of my travel expenses and payment (honoraria) for my time teaching according to international rules of industrial compliance Eucomed and FDA. Declared a personal non-pecuniary interest: Has been voted onto the council of the Royal College of Surgeons of England and is a Trustee of the organisation. Purpose to promote the highest standards of surgery in the UK. | |
| Third GDG Meeting 25 May 2012 | PC Declared a non personal pecuniary interest: Attended the OMERACT meeting, May 2012 in the USA. Travel and accommodation was paid by OMERACT. MD Declared personal non pecuniary interests: Weiya Zhang and he co-supervise a PhD student, Kun Zou, who is undertaking a systematic review and meta-analysis of placebo response in RCTs of complementary and alternative treatments for OA, which includes acupuncture. He is funded by a grant from the Chinese Government. He attended the OARSI meeting in Barcelona in April 25–28. His travel, registration and accommodation were funded by OARSI. He received there the OARSI Clinical Research Award for 2012, which included a personal prize of $2000. He will be attending EULAR in Berlin in June 5–9. His travel, registration and accommodation will be paid by EULAR since he is an invited speaker. In addition to speaking in the main programme (on management of gout) he will be attending meetings with other collaborators in relation to the OA Trial Bank initiative (no payment involved) and EULAR recommendations for non-pharmacological management of OA (no payment involved). He was also an invited speaker at the British Pain Society (BPS) at Liverpool 25 April 2011 for “Impact of context in the management of chronic pain”. Travel and hotel was covered by the BPS. KD Declared personal non-pecuniary interests: Attended OMERACT meeting 13–18th May 2012 to discuss outcome measures for trials in hand osteoarthritis. Attended the Osteoarthritis Research Society International, and travel and accommodation expenses were paid by the Arthritis Research UK National Primary Care Centre, her work place. Appointed joint lead for the Musculoskeletal CLRN in the North West Midlands. Grant holder on an acupuncture study (Whitehurst study) completed at Keele University. WZ Declared personal non pecuniary interests: One of his PhDs is currently undertaking meta-analysis of the placebo effect in acupuncture therapy. This is part of his thesis on “Comparison of the proportion of the placebo effect in trials for osteoarthritis’. Invited to give a talk on Safety of NSAIDs for the Expert Panel Meeting sponsored by Daiichi-Sankyo, Japan at the EULAR Annual Congress, Berlin 6–9 June 2012. Daiichi-Sankyo will pay for the hotel (2 nights) and flight cost for his trip to Berlin. Daiichi-Sankyo produces loxoprofen, both oral and topical formulations, which mainly sales in Asia and America (mainly south). EW Declared personal non-pecuniary interests: Attended the BSR Annual Meeting In Glasgow in May. The BSR accepts sponsorship from different drug companies. She did not have to pay an entry fee as she was chairing a session. She has also attended a meeting aimed at podiatrists about assessing feet biomechanics. It was run by Langer (a private company that sells insoles) although they did have to pay to attend. She attended a half day dermatology session run by Astellas Pharmaceuticals. JC Declared a personal non-pecuniary interest: Presentation on the use of hyaluronans given to Arthritis Care’s Helplines team 29th June 2012 by Sanofi. She will not be present but is declaring that she has management responsibilities for this staff group. RM Declared a personal non pecuniary interest: He attended the London Hip Meeting as speaker and chair of a session. His standard class rail travel will be paid by the conference organisers. JF Declared non personal pecuniary interest He is a member of the council in BIMM (British Medical Acupuncture Society) and is involved in postgraduate teaching, involving join injections and acupuncture. | |
| 4 July 2012 | PC Declared a personal pecuniary interest: Attended an advisory board of company who want to market a topical OA product called FLEXISEQ funded by Bollin Strategies for Pro Bono Bio UK. It will need to undergo Technology Appraisal; likely to be in late 2013 so will not be related to the timeframe of this guideline. MD Declared a non-personal non-specific pecuniary interest: Approached by a company called Ariel Pharmaceuticals who have a new analgesic compound that promises to show good efficacy and safety. Theoretically it should have no side-effects on the bowel, kidney or blood pressure. They have data in headache that shows good efficacy compared to oral NSAID. They have no data on OA but now want to do an RCT in OA and are keen to discuss Nottingham as the lead centre. If he took it on he would wish to compare the drug against both NSAID and paracetamol. The drug is not available commercially. He is keen to explore this further on behalf of Arthritis Research UK Pain Centre and possibly work towards an integrated programme of research on this novel compound that additionally includes animal models and focused human safety studies. This interest would not clash with the guideline timings. Declared personal specific non pecuniary interests: He attended the EULAR Congress in Berlin - no honorarium but his expenses were paid for by EULAR. The EULAR Textbook of Rheumatology was launched in Berlin – He is a co-editor and wrote the chapter on “Management of OA”. He will receive 500 euros honorarium for being a co-editor. KD Declared personal non-pecuniary interests: Delivered two presentations at EULAR Berlin 2012 5–9th June:
WZ Declared a non-personal non-specific pecuniary interest: Approached by a company called Ariel Pharmaceuticals who have a new analgesic compound that promises to show good efficacy and safety. Theoretically it should have no side-effects on the bowel, kidney or blood pressure. They have data in headache that shows good efficacy compared to oral NSAID. They have no data on OA but now want to do an RCT in OA and are keen to discuss Nottingham as the lead centre, and Weiya would be involved in developing the OA trial design. FB Declared personal non pecuniary interests Sponsorship to attend EULAR Berlin 2012 Servier (oral presentation) Regional Advisory Board Servier 13/3/12 Medical Liaison Training Servier 16/3/12 National Advisory Board Servier (Chair) 8/6/12 National Advisory Board-Servier Ireland (Chair) 12/9/12 Article for Servier Medicographia journal 1/9/12 All honoraria have been put into research accounts Co-author on the Atchia 2011 paper discussed as part of the evidence review. JC Declared personal non-pecuniary interests: Gave a presentation on the use of hyaluronans to Arthritis Care helplines team on the 29th June by Sanofi. Speaker at EULAR regarding PMR and comorbidities. Attended a meeting with Novartis regarding RA and biosimilars. MP Declared a personal non pecuniary interest: Speaking at a House of Commons meeting organised by Arthritis research UK to raise MPs’ awareness of OA and other musculoskeletal problems, and am speaking on “What musculoskeletal problems an average GP sees”. RM Declared a personal non pecuniary interest Speaker at The Great Debate in London (speaking on Hip Replacements) Conference organiser was Imperial College London who arranged hotel and paid travel by private car. VDN Declared a personal non-pecuniary interest. She attended an educational meeting on the diagnosis and management of fibromyalgia from the 27th to the 29th June and gave a presentation on guideline development to a panel of Russian and Israeli Clinicians. She did not attend sessions where Pfizer drugs were being discussed. Travel and expenses were paid by Pfizer and consultancy fee paid to the NCGC. Meeting was held in St. Petersburg, Russia. | |
| 25 September 2012 | PC Declared a personal pecuniary interests: Attended an advisory board on new anti-nerve growth factor therapy for OA (Fulranumab) developed by Janssen-Cillag. It is still in Phase III trial phase and is not related to the scope of this guideline. Funding will go into department. Attended an advisory board on new anti-nerve growth factor therapy for OA (Tanezumab) and is developed by Pfizer. It is still in Phase III trial phase and is not related to the scope of this guideline Funding will go into department. Declared a personal non-pecuniary interest: Speaker at RCP London on “What’s new in OA?” upon invitation from the RCP. BL Declared personal non pecuniary interest: He recently attended (Sept 13th–14th) the Royal College of Nursing’s Society of Orthopaedic and Trauma Nursing annual conference in Manchester. As Chair of the Society the RCN paid for his travel (second class rail ticket), conference fee and 2 night’s hotel accommodation. EW Declared personal pecuniary interests: Attended a drug advisory board meeting for a drug/device which is not let licensed made by Pro Bono Bio. The meeting was chaired by Phil Conaghan. The honorarium is going to her surgery. Wrote an article about the use of opioids in the management of back pain for a Pulse supplement. She will be paid for this but is unsure how much. Declared personal non-pecuniary interests: Servier (make protelos - an osteoporosis drug which had a recent study showing that it may be effective in OA) are arranging to do an osteoporosis and an osteoarthritis audit in a couple of surgeries to see what the cross over is. Her surgery and Elspeth are involved and are not getting paid for this. She is advising Servier as to what they may want to search for in the audit. Wrote some comments on 2 reports about the EULAR meeting for guidelines in practice. They were mainly about rheumatoid and all experimental so not OA related. MP Declared a personal non pecuniary interest: Presenting at RCGP annual conference 5th Oct 2012 a short update for GPs on OA, covering diagnosis and treatment - will present data from two studies: adverse events from paracetamol in patients with knee OA and benefit of exercise in patients with knee OA. | |
| 7 November 2012 | MD Declared a personal non-pecuniary interest: Went to Tel Aviv (Oct 23rd – 26th) to help run their First Advanced Course on Physical Examination organised by the Israeli Society of Rheumatology. The Society covered the expenses for his travel, hotel (Tel Aviv - where the meeting was held) and subsistence. They also purchased from Academic Rheumatology, Nottingham, 50 facsimile copies of one of his books on Physical Examination (Doherty and Doherty) at cost price to give to the delegates (no profit to him). The meeting focused totally on musculoskeletal clinical skills and had no content relating to management (of OA or any other rheumatic condition). KD Declared personal non-pecuniary interests: Attended a learning and listening event on the 30th October at the Chartered Society of Physiotherapy (CSP). The travel was funded by the CSP. BL Declared a personal non pecuniary interest: Chair of the RCN Society of Orthopaedic and Trauma Nursing (SOTN). Members of ARMA (Arthritis and Musculoskeletal Alliance) and does occasionally attend some ARMA meetings (unpaid). JC Declared a non-personal non-pecuniary interest: Merck Sharpe Dohme has just agreed to give Arthritis care funding to reprint their existing Living with OA Booklet. No changes to the content are expected as this is just a print run. They do need to check for minor amendments also to ensure it is current e.g. that the contact details for other support charities or organisations listed in the back pages. This is part of their commitment to the DoH Information Standard. MSD do not have any input to any of the reprinted booklet’s contents and all editorial rights remain with Arthritis Care. MP Declared a personal non pecuniary interest: Will deliver a talk at RCGP One Day Essentials Musculoskeletal Meeting on the 20th of November. Travel expenses and speaker fees of £150. RM Declared a non personal non pecuniary interest: The Royal Bournemouth Hospital Trust received a grant from Zimme UK to fund Clinical Fellow in Orthopaedics (Zimmer UK is an orthopaedic implant company). Declared a personal non pecuniary interest: Principle investigator in research application to sport England to fund a study into hip arthritis and exercise/sport. | |
| 18 December 2012 | MD Declared a personal pecuniary specific interest December 12th – MD attended a whole day ad hoc advisory board for Neusentis (Pfizer) in Cambridge, UK to discuss the study designs to test a new urate lowering agent. His travel expenses (car – no accommodation required) were covered and he will receive a personal honorarium (£2000) in due course. Declared a personal pecuniary non-specific interests December 10th – MD attended the French Rheumatology Association meeting in Paris to talk on Gout (Patient and Health Care Provider Barriers to Care). The cost of his expenses (return train, 1 night’s accommodation) was covered by the meeting. 16th/17th December – MD will attend a meeting in Florence to finalise a multi-author review on risks related to high and low uric acid levels. Menarini (Italy) will pay for the travel and 1 night’s accommodation/subsistence (no honorarium involved). WZ Declared a personal pecuniary non-specific interests WZ was invited by Asia Pacific League of Association for Rheumatology (APLAR) to give a talk on Evidence based diagnosis and management of osteoarthritis in Shanghai on 19th Jan 2013. Travel and hotel will be paid. EW Declared personal non-pecuniary non-specific interests EW attended a day course on dermatology run by Astellas and is not aware of Astellas making any products related to OA. EW attended the Primary Care Rheumatology Society Annual Meeting - self funded. Declared Personal pecuniary non-specific interests EW attended the American College of Rheumatology Meeting sponsored by the Primary Care Rheumatology Society. EW presented at a BMJ Musculoskeletal Master class in Abu Dhabi - funded by BMJ publishing. FB Declared Personal non-pecuniary specific interests FB working with Arthritis Care on an educational webcast for patients with Osteoarthritis. FB reviewing Osteoarthritis pathway for Map of Medicine. IB Declared Personal pecuniary non-specific interests IB lectured at the King’s Fund on Tuesday 27th November on developing an integrated care model for musculoskeletal services in NHS NW London. The meeting was sponsored by Pfizer. IB received dinner and has been promised an honorarium of £250. The reps were not present during the meeting and IB did not meet with them before or after the meeting. IB attended a lecture at ARMA on Wednesday 21st November and was invited to dinner to meet Martin McShane, Director of Domain 2 (Long Term Conditions) at the NHS Commissioning Board. The lecture and dinner were sponsored by Roche. IB attended a clinical meeting at Gordon House Surgery on Wednesday 14th November. The meeting was sponsored by Pfizer, who were promoting Viagra. No musculoskeletal drugs were discussed. Sandwiches were provided. No attendees received any money, gifts or professional samples from Pfizer. Personal pecuniary non-specific. IB attended a clinical network meeting at ARMA on Thursday 22nd November as a national clinical advisor and did not receive any payment. IB declared his interest with ARMA at the initial declaration. | MD will be asked to withdraw from discussions where Celebrex (Pfizer) will be listed as a comparator. |
| 30 January 2013 | PC Declared personal non-pecuniary specific interests: PC has revised Map of Medicine OA pathway Speaker at Keele University “Imaging as a biomarker in OA. | MD left the room at 13.35 for the discussions regarding the paracetamol versus celecoxib comparison (regarding a conflict of interest declared on the 18th December GDG meeting). |
| 12 March 2013 | KD Declared personal non-pecuniary interests: KD will attend the Oxford University Evidence Live conference on the 25th March and will attend the British Society for Rheumatology OA Special Interest Group OA Trial Bank talk and will facilitate a workshop hand OA. WZ Declared a personal non-specific pecuniary interest: WZ will chair a panel discussion about topical NSAIDs in OA at EULAR 2013, Madrid, 12–15 June. The meeting will be sponsored by Daiichi Sankyo (which produces loxoprofen both oral and patch products). WZ’s travel, hotel expense and honorarium (1000 euros) will be covered. WZ may withdraw from GDG discussions whenever topical NSAIDS are discussed (as a comparator as we are not looking at them as part of the scope). Declared a personal specific pecuniary interest: WZ will present the clinical practice guidelines of OA (CG59) in the Peking University OA International Forum, Beijing 6–8 Sept 2013. WZ’s travel, hotel and honorarium will be paid. BL Declared personal non pecuniary interests: Chair of the RCN Society of Orthopaedic and Trauma Nursing (SOTN). Members of ARMA (Arthritis and Musculoskeletal Alliance) and does occasionally attend some ARMA meetings (unpaid). Wrote an article for ‘Nursing and Residential Care’ magazine on caring for older people with wrist and hand problems (including OA) in Feb 2013. JC Declared a personal pecuniary interest: Received travel and accommodation expenses to attend a meeting in Madrid on 11th June from AbbVie. However this was about RA as part of their global campaign RA – Join the Fight. MP Declared a personal non-pecuniary interest: MP has been asked to join the review panel for the knee OA options grid. The Option Grid Collaborative is not for profit and operates under a Creative Commons License. The value of these tools was clear during the MAGIC Programme (Health Foundation) on how best to do shared decision making in the NHS (2010–2012). RM Declared a personal non-pecuniary interest: RM gave a lecture to patient group on the prevention and treatment of OA. Declared a personal non-specific pecuniary interest: RM is also the director of a consultancy that provides DVT devices. | |
| 1 May 2013 | PK Declared a personal pecuniary interest: Appointed as MSK director and visiting Professor at Christchurch University. RM Declared a personal non-pecuniary interest: Principle Investigator in the Chain Study (Cycling against hip pain ) In the treatment of Osteoarthritis using Cycling Exercise. Sponsored by Dorset Clinical Commissioning Group, Active Dorset, Bournemouth Borough Council and Bournemouth and Christchurch GP Localities. | |
| 5 June 2013 | PC Declared personal non-pecuniary interests: Co-author on the EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis published April 2013. Co-author on a clinical review on holistic approach in OA, published in March 2012. Co-author on a clinical review on current treatment in OA, published in October 2012. Co-author on a clinical review entitled “New horizons in OA”, published in 2013. KD Declared a non-personal pecuniary interest: Received a reviewing grant from the Department of Health in Norway. Travel and accommodation has also been funded. BL Declared personal non pecuniary interests: Co-author of two chapters for forthcoming orthopaedic nursing textbook - ‘The team approach and nursing roles in orthopaedic and musculoskeletal trauma care’ and ‘Elective Orthopaedic Surgery’. Book due to be published January 2014. Will be attending the RCN SOTN annual conference in Glasgow (Sept 12–13th). As Chair of the Society the RCN will pay for travel (second class rail ticket, conference fee and 2 night’s hotel accommodation. EW Declared personal non-pecuniary interest EW is currently writing an article on the management of OA for a supplement for guidelines in practice, i.e. all about CG59. It’s paid by the publishers but is sponsored by Movelat which is a topical gel, licensed for the use of musculoskeletal pain. | |
| 24 October 2013 | PC Declared a personal pecuniary interest PC is participating in a advisory board to develop a new NSAID in November 2013 for Infirst. IR Declared a personal pecuniary interest IR was a course organiser and lecturer at a muscoskeletal education workshop in October 2013. The meeting was organised by NHS Ealing Clinical Commissioning Group (CCG) and sponsored by Pfizer. A payment of £600 was received for organising the course was received from NHS Ealing CCG. IR also received an honorarium of £100 and travel expenses for speaking at the British Institute of Muscoskeletal Medicine annual symposium in December. Declared a non pecuniary interest IR was a lecturer at the Association for Medical Osteopathy presenting the draft OA guidelines and discussing the LETR. No payment or hospitality has been received. WZ Declared a personal pecuniary interest WZ is an invited speaker at the 2nd World Congress on Controversies, Debates and Consensus in Bone, Muscle and Joint Diseases (BMJD) taking place in November 21–24 2013, in Brussels, Belgium. WZ will receive travel and accommodation expenses. FB Declared a personal pecuniary interest FB presented at BMJ Masterclass on 22nd November 2013 and will receive £350 honorarium plus expenses. FB will be a speaker at Pulse conference on 3rd December 2013 and will receive £250 honoarium plus expenses. KD Declared a personal pecuniary interest KD presented on the draft NICE OA guideline during consultation to Rheumatology registrars. KD presented at the AGILE physiotherapy therapy on the 2008 NICE OA guideline and received accommodation. EW Declared a non-personal pecuniary interest Attended a BMJ Masterclass in September 2013. JC Declared a personal pecuniary interest Participated in a media event for DePuy hip joints and prosthetics for which a £600 honorarium was paid directly to Arthritis Care. An attendance fee was received from Bone and Musclen Joint Disease congress sponsored by Abbvie to enable a poster presentation to be submitted. £490 was received for the conference registration which was submitted directly to Arthritis Care. MD Declared a personal non-pecuniary interest MD wrote a review on Abersheck about placebo mechanisms for which no payment or hospitality was received. MD spoke at Ono to discuss a novel drug for pain in OA for which no payment or hospitality was received. MD was a speaker at a conference in Liverpool in October 2013 to discuss rare diseases in cartilidge for which no payment or hospitality was received. |
- Declarations of interest - OsteoarthritisDeclarations of interest - Osteoarthritis
- 517DNA1517DNA1biosample
- Mus musculus PDZ and LIM domain 2 (Pdlim2), transcript variant 2, mRNAMus musculus PDZ and LIM domain 2 (Pdlim2), transcript variant 2, mRNAgi|359279897|ref|NM_001253736.1|Nucleotide
- cytochrome oxidase subunit 1, partial (mitochondrion) [Palliolum tigerinum]cytochrome oxidase subunit 1, partial (mitochondrion) [Palliolum tigerinum]gi|1430074521|gb|AXC47342.1|Protein
- histone H3, partial [Palliolum tigerinum]histone H3, partial [Palliolum tigerinum]gi|395395349|gb|AFN55293.1|Protein
Your browsing activity is empty.
Activity recording is turned off.
See more...